Enzon names Dr. Ivan Horak Chief Scientifc Officer
Enzon Pharmaceuticals, Inc. announced the appointment of Ivan Horak, M.D. to the position of Executive Vice President of Research and Development and Chief Scientific Officer. In his new position Dr. Horak will oversee all aspects of Enzon's research and development, regulatory affairs, and quality assurance activities.
Dr. Horak brings an impressive background in drug development to Enzon and is a board certified medical oncologist. He has held a number of senior medical and scientific positions in the pharmaceutical industry, as well as the National Cancer Institute (NCI).
Dr. Horak joins Enzon from Immunomedics, Inc., where he served as Chief Scientific Officer since July 2003 and Executive Vice President of Research and Development since May 2002. Before joining Immunomedics, Dr. Horak was employed by Pharmacia as a Vice President for Clinical Oncology, where he helped direct the global development of oncology compounds from 1999 to 2002, including Camptosar® for metastatic colorectal cancer.
From 1996 to 1999, Dr. Horak held a variety of clinical research positions at Janssen Research Foundation, a subsidiary of the Johnson & Johnson Company, including International Director for Clinical Research and Development, Oncology.
Prior to joining Janssen, Dr. Horak spent nine years at the NCI where he most recently served as a cancer expert for the Metabolism Branch.
In addition to over 50 scientific publications, Dr. Horak is a member of several prominent medical societies and has served on various committees for the American Association for Cancer Research and the International Union Against Cancer. He also serves on the editorial board of the prestigious journal, Cancer Research.
Other news from the department people
